Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.36% | 10.01% | 7.80% | 5.06% | 3.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.36% | 10.01% | 7.80% | 5.06% | 3.70% |
| Cost of Revenue | 103.56% | 126.85% | -1,785.85% | -140.39% | -131.49% |
| Gross Profit | 4.25% | -10.00% | 25.18% | 74.65% | 41.19% |
| SG&A Expenses | 21.49% | 29.97% | 149.27% | 186.10% | 143.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.09% | 118.93% | 119.37% | -14.20% | 11.08% |
| Operating Income | 8.91% | -16.38% | -13.53% | 19.53% | 0.25% |
| Income Before Tax | -9.94% | -19.30% | -23.31% | -0.57% | -24.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.94% | -19.30% | -23.31% | -0.57% | -24.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.85% | 16.95% | 21.34% | -17.26% | 5.50% |
| Net Income | -12.11% | -20.78% | -24.53% | -10.37% | -33.29% |
| EBIT | 8.91% | -16.38% | -13.53% | 19.53% | 0.25% |
| EBITDA | 158.51% | 590.27% | -- | -- | 6.45% |
| EPS Basic | -12.99% | -19.87% | -23.48% | -7.57% | -36.07% |
| Normalized Basic EPS | 20.13% | -36.43% | -18.55% | 15.17% | 2.47% |
| EPS Diluted | -12.86% | -19.71% | -23.43% | -7.71% | -36.16% |
| Normalized Diluted EPS | 19.52% | -36.07% | -18.56% | 9.08% | 10.01% |
| Average Basic Shares Outstanding | 0.21% | -1.37% | -3.90% | -4.62% | 4.83% |
| Average Diluted Shares Outstanding | -2.72% | -4.00% | -5.18% | -5.05% | -4.01% |
| Dividend Per Share | 6.32% | 5.81% | 5.29% | 4.76% | 4.82% |
| Payout Ratio | 0.23% | 0.34% | 0.36% | 0.12% | 0.52% |